Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct;8(19):1253.
doi: 10.21037/atm-2020-71.

A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma

Nishal Ravindran  1 , Paul J Thuluvath  1   2
Affiliations
Editorial

A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma

Nishal Ravindran et al. Ann Transl Med. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-2020-71). The authors have no conflicts of interest to declare.

Comment on

References

    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350-5. 10.1126/science.aar4060 - DOI - PMC - PubMed
    1. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol 2016;39:98-106. 10.1097/COC.0000000000000239 - DOI - PMC - PubMed
    1. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502. 10.1016/S0140-6736(17)31046-2 - DOI - PMC - PubMed
    1. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52. 10.1016/S1470-2045(18)30351-6 - DOI - PubMed
    1. Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020;21:571-80. 10.1016/S1470-2045(20)30011-5 - DOI - PubMed